February 16, 2021

Nature Article Cites IgE Antibodies as a Technology to Watch in 2021 and Notes their Potential as an Anti-Cancer Therapy

January 19, 2021

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

January 6, 2021

Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors

November 9, 2020

Epsilogen Announces Formation of Clinical Advisory Board

October 22, 2020

ALSA Ventures webinar: Investing in biotechnology in the COVID era

October 14, 2020

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

October 12, 2020

Featured on EurekAlert!

ALSA Ventures launches European biotech clinical accelerator 'Eclipse'

October 12, 2020

ALSA Ventures Launches European Biotech Clinical Accelerator ‘Eclipse’ to speed preclinical assets into the clinic

September 29, 2020

Dr. Karen Zinkewich-Péotti brings brings strong R&D leadership experience from both international biopharmaceutical companies and smaller biotech

September 22, 2020

Featured on Endpoints News

Ex-CRO boss scores veteran VCs and $59M for his Euro-focused fund

September 16, 2020

ALSA Ventures today announced first closing of its European biotechnology investment fund with commitments of US$59M

July 20, 2020

Epsilogen announces further UK government funding to develop next generation antibody treatments for ovarian cancer

June 30, 2020

ALSA Ventures Webinar: European Biotech Investments for Family Offices

April 27, 2020

Encouraging interim data from a phase 1 clinical study evaluating MOv18 IgE in cancer patients with advanced solid tumours presented at the AACR Virtual Annual Meeting

April 20, 2020

Interim phase 1 data evaluating MOv18 IgE, an anti-folate receptor alpha IgE antibody, in cancer patients with advanced solid tumours to be presented at the AACR Virtual Annual Meeting I

April 20, 2020

Epsilogen licences MOv18 IgE, an anti-folate receptor alpha IgE antibody from King’s College London

March 31, 2020

Oxford BioTherapeutics Announces Second Oncology Drug Candidate Selected to Advance into Formal IND Enabling Studies from Boehringer Ingelheim Collaboration

February 20, 2020

Montis Biosciences launched with €8,4 million seed financing and a novel approach to immune-oncology

January 9, 2020

Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors

August 27, 2019

IGEM Therapeutics announces final close of £5 million Series A financing round